1.Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
2.Oh D-Y, Bang Y-J. HER2-targeted therapies—a role beyond breast cancer. Nat Rev Clin Oncol. 2019:1–16.
3.Pegram MD, Miles D, Tsui CK, Zong Y. HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody–Drug Conjugate Drug Development in Solid Tumors. Clin Cancer Res. 2019.
4.Domínguez-Ríos R, Sánchez-Ramírez DR, Ruiz-Saray K, Oceguera-Basurto PE, Almada M, Juárez J, et al. Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy. Colloid Surf B-Biointerfaces. 2019;178:199–207.
5.Mazzotta M, Krasniqi E, Barchiesi G, Pizzuti L, Tomao F, Barba M, et al. Long-term safety and real-world effectiveness of trastuzumab in breast cancer. J Clin Med. 2019;8:254.
6.Bonelli P, Borrelli A, Tuccillo FM, Silvestro L, Palaia R, Buonaguro FM. Precision medicine in gastric cancer. World J Gastroenterol. 2019;11:804–29.
7.Eiger D, Pondé NF, de Azambuja E. Pertuzumab in HER2-positive early breast cancer: current use and perspectives. Future Oncol. 2019;15:1823–43.
8.Chen Y, Liu L, Ni R, Zhou W. Advances in HER2 testing. Adv Clin Chem. 2019;91:123–62.
9.Jauw YW, O’Donoghue JA, Zijlstra JM, Hoekstra OS, Menke-van der Houven CW, Morschhauser F, et al. 89Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo. J Nucl Med. 2019;60:1825–32.
10.Massicano AV, Lee S, Crenshaw BK, Aweda TA, El Sayed R, Super I, et al. Imaging of HER2 with [89Zr] pertuzumab in Response to T-DM1 Therapy. Cancer Biother Radiopharm. 2019;34:209–17.
11.Liang Q, Kong L, Zhu X, Du Y, Tian J. Noninvasive Imaging for Assessment of the Efficacy of Therapeutic Agents for Hepatocellular Carcinoma. Mol Imaging Biol. 2019:1–14.
12.Mankoff DA, Farwell MD, Clark AS, Pryma DA. Making molecular imaging a clinical tool for precision oncology: a review. JAMA Oncol. 2017;3:695–701.
13.Menon H, Guo C, Verma V, Simone CB. The Role of Positron Emission Tomography Imaging in Radiotherapy Target Delineation. PET Clin. 2020;15:45–53.
14.Provost J, Garofalakis A, Sourdon J, Bouda D, Berthon B, Viel T, et al. Simultaneous positron emission tomography and ultrafast ultrasound for hybrid molecular, anatomical and functional imaging. Nat Biomed Eng. 2018;2:85–94.
15.Marcu LG, Moghaddasi L, Bezak E. Imaging of tumor characteristics and molecular pathways with PET: developments over the last decade toward personalized cancer therapy. International Journal of Radiation Oncology* Biology* Physics. 2018;102:1165–82.
16.Aluicio‐Sarduy E, Ellison PA, Barnhart TE, Cai W, Nickles RJ, Engle JW. PET radiometals for antibody labeling. J Lablled Compd Rad. 2018;61:636–51.
17.Woo S-K, Jang SJ, Seo M-J, Park JH, Kim BS, Kim EJ, et al. Development of 64Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies. J Nucl Med. 2019;60:26–33.
18.Moek KL, Giesen D, Kok IC, de Groot DJA, Jalving M, Fehrmann RS, et al. Theranostics using antibodies and antibody-related therapeutics. J Nucl Med. 2017;58:83S–90S.
19.Dehdashti F, Wu N, Bose R, Naughton MJ, Ma CX, Marquez-Nostra BV, et al. Evaluation of [89 Zr] trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. Breast Cancer Res Treat. 2018;169:523–30.
20.O’Donoghue JA, Lewis JS, Pandit-Taskar N, Fleming SE, Schöder H, Larson SM, et al. Pharmacokinetics, biodistribution, and radiation dosimetry for 89Zr-trastuzumab in patients with esophagogastric cancer. J Nucl Med. 2018;59:161–6.
21.De A, Kuppusamy G, Karri VVSR. Affibody molecules for molecular imaging and targeted drug delivery in the management of breast cancer. Int J Biol Macromol. 2018;107:906–19.
22.Gebauer M, Skerra A. Engineering of binding functions into proteins. Curr Opin Biotechnol. 2019;60:230–41.
23.Kramer-Marek G, Bernardo M, Kiesewetter DO, Bagci U, Kuban M, Omer A, et al. PET of HER2-positive pulmonary metastases with 18F-ZHER2: 342 affibody in a murine model of breast cancer: comparison with 18F-FDG. J Nucl Med. 2012;53:939–46.
24.Yanai A, Harada R, Iwata R, Yoshikawa T, Ishikawa Y, Furumoto S, et al. Site-Specific Labeling of F–18 Proteins Using a Supplemented Cell-Free Protein Synthesis System and O–2-[18 F] Fluoroethyl-L-Tyrosine:[18 F] FET-HER2 Affibody Molecule. Mol Imaging Biol. 2019;21:529–37.
25.Velikyan I, Schweighöfer P, Feldwisch J, Seemann J, Frejd FY, Lindman H, et al. Diagnostic HER2-binding radiopharmaceutical,[68Ga] Ga-ABY–025, for routine clinical use in breast cancer patients. Am J Nucl Med Mol Imaging. 2019;9:12–23.
26.Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J. [18 F] FBEM-Z HER2: 342-Affibody molecule—a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging. 2008;35:1008–18.
27.Sandström M, Lindskog K, Velikyan I, Wennborg A, Feldwisch J, Sandberg D, et al. Biodistribution and radiation dosimetry of the anti-HER2 affibody molecule 68Ga-ABY–025 in breast cancer patients. J Nucl Med. 2016;57:867–71.
28.Sörensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, et al. Measuring HER2-receptor expression in metastatic breast cancer using [68Ga] ABY–025 Affibody PET/CT. Theranostics. 2016;6:262–71.
29.Heskamp S, Raavé R, Boerman O, Rijpkema M, Goncalves V, Denat F. 89Zr-immuno-positron emission tomography in oncology: state-of-the-art 89Zr radiochemistry. Bioconjug Chem. 2017;28:2211–23.
30.Brandt M, Cardinale J, Aulsebrook ML, Gasser G, Mindt TL. An overview of PET radiochemistry, part 2: Radiometals. J Nucl Med. 2018;59:1500–6.
31.Dilworth JR, Pascu SI. The chemistry of PET imaging with zirconium–89. Chem Soc Rev. 2018;47:2554–71.
32.Xu Y, Bai Z, Huang Q, Pan Y, Pan D, Wang L, et al. PET of HER2 expression with a novel 18FAl labeled affibody. J Cancer. 2017;8:1170–8.
33.Xu Y, Wang L, Pan D, Yu C, Mi B, Huang Q, et al. PET imaging of a 68Ga labeled modified HER2 affibody in breast cancers: from xenografts to patients. Br J Radiol. 2019;92:20190425.
34.Mason C, Kossatz S, Carter L, Pirovano G, Brand C, Guru N, et al. A 89Zr-HDL PET tracer monitors response to a CSF1R inhibitor. J Nucl Med. 2019:jnumed. 119.230466.
35.Raavé R, Sandker G, Adumeau P, Jacobsen CB, Mangin F, Meyer M, et al. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89 Zr-immunoPET. Eur J Nucl Med Mol Imaging. 2019;46:1966–77.
36.Garousi J, Andersson KG, Mitran B, Pichl M-L, Ståhl S, Orlova A, et al. PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR: 2377 affibody molecules. Int J Oncol. 2016;48:1325–32.
37.Sörensen J, Sandberg D, Sandström M, Wennborg A, Feldwisch J, Tolmachev V, et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY–025 affibody molecule. J Nucl Med. 2014;55:730–5.